VX 702

Drug Profile

VX 702

Alternative Names: KVK-702; VX-702

Latest Information Update: 27 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Kissei Pharmaceutical; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Phenylurea compounds
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Cardiovascular disorders; Rheumatoid arthritis

Most Recent Events

  • 31 Mar 2009 No development reported - Phase-I for Rheumatoid arthritis in Japan (PO)
  • 31 Mar 2009 No development reported - Phase-II for Rheumatoid arthritis in Europe (PO)
  • 14 Jun 2008 Pooled efficacy, pharmcaodynamic and safety data from two phase II trials in Rheumatoid arthritis presented at the Annual European Congress of Rheumatology (EULAR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top